Empagliflozin and Metformin for Type 2 Diabetes Management

Introduction to Combination Therapy

The American Diabetes Association recommends metformin as the first-line pharmacotherapy for type 2 diabetes due to its effectiveness, safety, low cost, and potential to reduce cardiovascular events and mortality 2
Empagliflozin has demonstrated significant cardiovascular benefits, including reduction in the composite of cardiovascular death, myocardial infarction, or stroke (HR 0.80 [95% CI 0.67–0.95]), as well as lower risk of hospitalizations for heart failure (HR 0.61 [95% CI 0.47–0.80]) 1

For patients with renal impairment, if eGFR is 30-44 mL/min/1.73 m², metformin dose should be reduced to 1000 mg/day, and empagliflozin can be used at 10 mg daily 3
Both medications are contraindicated if eGFR is <30 mL/min/1.73 m² 3

Common side effects of empagliflozin include genital mycotic infections (occurring in approximately 6% of patients) 3
Patients should be monitored for potential side effects of SGLT2 inhibitors, including genital mycotic infections, volume depletion, and risk of euglycemic diabetic ketoacidosis 3
Metformin's main side effects are gastrointestinal intolerance (bloating, abdominal discomfort, diarrhea), which can be mitigated by gradual dose titration 2

For patients with established cardiovascular disease or high cardiovascular risk, the combination of empagliflozin and metformin is particularly beneficial due to the cardiovascular protective effects of empagliflozin 1, 4
Long-term use of metformin may be associated with vitamin B12 deficiency, so periodic testing of vitamin B12 levels should be considered 2